Insights from IgE Immune Surveillance in Allergy and Cancer for Anti-Tumour IgE Treatments

Alex J. McCraw, Jitesh Chauhan, Heather J. Bax, Chara Stavraka, Gabriel Osborn, Melanie Grandits, Jacobo López-Abente, Debra H. Josephs, James Spicer, Gerd K. Wagner, Sophia N. Karagiannis, Alicia Chenoweth*, Silvia Crescioli*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

9 Downloads (Pure)

Abstract

IgE, the predominant antibody class of the allergic response, is known for its roles in protecting against parasites; however, a growing body of evidence indicates a significant role for IgE and its associated effector cells in tumour immunosurveillance, highlighted by the field of AllergoOncology and the successes of the first-in-class IgE cancer therapeutic MOv18. Supporting this concept, substantial epidemiological data ascribe potential roles for IgE, allergy, and atopy in protecting against specific tumour types, with a corresponding increased cancer risk associated with IgE immunodeficiency. Here, we consider how epidemiological data in combination with functional data reveals a complex interplay of IgE and allergy with cancer, which cannot be explained solely by one of the existing conventional hypotheses. We furthermore discuss how, in turn, such data may be used to inform future therapeutic approaches, including the clinical management of different patient groups. With epidemiological findings highlighting several high-risk cancer types protected against by high IgE levels, it is possible that use of IgE-based therapeutics for a range of malignant indications may offer efficacy to complement that of established IgG-class antibodies.
Original languageEnglish
Article number4460
Number of pages17
JournalCancers
Volume13
Issue number17
DOIs
Publication statusPublished - 04 Sep 2021

Keywords

  • IgE
  • antibodies
  • cancer
  • immunotherapy
  • AllergoOncology

Fingerprint

Dive into the research topics of 'Insights from IgE Immune Surveillance in Allergy and Cancer for Anti-Tumour IgE Treatments'. Together they form a unique fingerprint.

Cite this